NAD+ + Glutathione + Sermorelin Research Data

Natural Aminos Research Stack or Formula of the Day

NAD+ + Glutathione + Sermorelin

Cellular Bioenergetics, Redox Defense & GH-IGF-1 Signaling Research Spotlight

Compound Identity & Current Evidence Context

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide used in cellular redox reactions, mitochondrial energy metabolism, DNA-repair signaling, and NAD+-dependent enzymes including sirtuins, PARPs and CD38. The scientific literature on NAD biology is extensive, but evidence for directly administered NAD+ is much thinner than the literature on oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). A 2026 systematic review found consistent biochemical target engagement with NR/NMN in humans but heterogeneous clinical outcomes, and identified no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness. A 2019 human IV pilot primarily described the metabolic fate of infused NAD+, while a 2026 retrospective commercial-setting study reported short-term tolerability data rather than proof of clinical efficacy.

Glutathione (GSH) is the endogenous tripeptide gamma-glutamyl-cysteinyl-glycine and one of the major intracellular redox buffers. Reduced GSH participates in peroxide detoxification, xenobiotic conjugation, thiol redox control and recycling of oxidized glutathione through the NADPH-dependent glutathione-reductase system. Human evidence shows that some oral formulations can raise measurable glutathione stores, but clinical outcome studies are indication- and route-specific. Intravenous glutathione has been evaluated in small controlled studies, including Parkinson disease, without establishing broad clinical benefit. Route and manufacturing quality are especially important: in August 2026 FDA reported at least 30 adverse events following IV glutathione compounded from dietary-supplement-grade material and warned that such ingredients are inappropriate for injectable drugs.

Sermorelin is the 29-amino-acid amino-terminal fragment of human growth hormone-releasing hormone, often described as GHRH(1-29). It stimulates the pituitary GHRH receptor and increases endogenous growth-hormone (GH) release, which can raise insulin-like growth factor-1 (IGF-1). Sermorelin acetate was previously marketed in the United States as Geref and received FDA approval for pediatric growth-hormone deficiency; the commercial product was later withdrawn from the market, with FDA records noting that the withdrawal was not for safety or effectiveness reasons. Human studies of GHRH(1-29) show acute and repeated increases in GH and IGF-1, including pediatric growth studies and small studies in older adults. Evidence for routine anti-aging, recovery or body-composition use remains limited and should not be inferred from the historical pediatric indication.

No peer-reviewed human, animal or cell study was identified that administered NAD+ + glutathione + sermorelin together as a defined three-component intervention. No controlled study was identified establishing pharmacokinetic compatibility, additive efficacy or long-term safety for the exact stack. The complete combination must therefore be evaluated from separate component evidence and mechanistic theory rather than direct proof.

Benefits

NAD+

NAD+ is indispensable for energy metabolism because NAD+/NADH couples transfer electrons through glycolysis, fatty-acid oxidation and the tricarboxylic-acid cycle, ultimately supporting mitochondrial ATP production. NAD+ also serves as a substrate for sirtuins and DNA-repair enzymes. These functions create a strong biological rationale for studying NAD homeostasis in aging and metabolic disease, but biological necessity does not mean that exogenous NAD+ infusion produces a clinical benefit in otherwise healthy people.

The strongest modern human evidence for NAD boosting comes from precursors rather than direct NAD+. The 2026 PRISMA-guided review of 33 human intervention studies found that NR and NMN generally increased NAD-related metabolites but produced mixed or null effects across metabolic, vascular and functional endpoints. Direct IV NAD+ evidence remains preliminary. In the 2019 six-hour infusion pilot, infused NAD+ was rapidly removed from plasma and generated measurable downstream metabolites; the study did not test recovery, longevity, body composition or performance outcomes. A 2026 retrospective comparison of four daily 500-mg IV NAD+ versus IV NR infusions found that NAD+ infusions commonly produced gastrointestinal symptoms, increased heart rate and chest pressure during administration, while laboratory outcomes over 30 days were largely unchanged and exploratory.

Glutathione

Glutathione has direct human evidence for increasing body glutathione status. In a six-month randomized, double-blind, placebo-controlled study of 54 adults, daily oral glutathione increased glutathione in blood and multiple cellular compartments, with dose- and time-dependent effects and a lower oxidized-to-reduced glutathione ratio. A 2026 randomized crossover study also reported that a micellar oral formulation produced greater systemic glutathione exposure than standard oral glutathione in a small healthy cohort. These studies demonstrate biochemical exposure and redox effects, not a universal treatment effect.

Clinical outcomes are mixed. A randomized double-blind IV glutathione pilot in Parkinson disease enrolled 21 participants and found acceptable short-term tolerability but no significant difference in Unified Parkinson Disease Rating Scale change. In cystic fibrosis, a multicenter randomized oral-glutathione trial did not significantly improve the primary growth endpoint. These results reinforce the distinction between improving a redox biomarker and proving a disease-modifying or performance benefit.

Sermorelin

Sermorelin/GHRH(1-29) has clear human endocrine pharmacology. In healthy older men, short-term twice-daily subcutaneous GHRH(1-29) produced dose-related increases in 24-hour GH secretion and IGF-1; the higher dose restored those measures toward levels seen in younger men without significant short-term changes in fasting glucose, blood pressure or routine chemistry. In a multicenter pediatric study of 110 previously untreated GH-deficient children, daily GHRH(1-29) approximately doubled average height velocity during the first six months and maintained improved growth through one year in the evaluable cohort.

Longer GHRH-analog studies in older adults provide adjacent evidence rather than exact proof for current sermorelin products. A 16-week study in 19 adults aged 55-71 increased nocturnal GH and IGF-1 and increased lean body mass in men; a later 20-week randomized GHRH trial in 152 older adults reported improved composite cognition and reduced body fat, but also increased fasting insulin in the mild-cognitive-impairment subgroup. These findings support biological activity of the GHRH-GH-IGF-1 axis while also showing that endocrine stimulation can alter glucose-insulin physiology and that clinical benefits are not uniformly established.

What the Formulas Are Studied For

NAD+ Research Areas

Cellular energy metabolism and mitochondrial redox reactions.

NAD+-dependent sirtuin, PARP and CD38 signaling.

Age-related changes in NAD homeostasis and metabolic resilience.

NR/NMN precursor strategies for increasing NAD-related metabolites.

Direct IV NAD+ pharmacokinetics and short-term infusion tolerability.

DNA-repair, stress-response and cellular-survival pathways.

No established FDA-approved anti-aging or wellness indication for IV NAD+.

Glutathione Research Areas

Cellular antioxidant defense and peroxide detoxification.

GSH/GSSG redox balance and oxidative-stress biomarkers.

Glutathione-S-transferase conjugation and xenobiotic handling.

Immune-cell redox biology and inflammatory signaling.

Oral bioavailability and restoration of measurable glutathione stores.

Route-specific clinical studies including neurologic, liver, dermatologic and pulmonary research.

Sterile injectable-product quality and endotoxin risk.

Sermorelin Research Areas

Pituitary GHRH-receptor stimulation and endogenous GH release.

IGF-1 restoration and GH pulsatility.

Historical treatment of pediatric growth-hormone deficiency.

Age-related decline in the GH-IGF-1 axis.

Body-composition, lean-mass and adiposity research with GHRH analogs.

Cognition and neuroendocrine aging research with GHRH stimulation.

Not established as an approved anti-aging, recovery or general body-composition therapy.

Published Research - Worldwide Evidence Review

NAD+ - Australia, United States and 2026 International Evidence

The most direct published IV NAD+ pharmacokinetic study was led by Australian and U.S. investigators in 2019. During a six-hour infusion, plasma NAD+ did not simply accumulate; it was rapidly removed from circulation during the early infusion period, with later changes in urinary NAD+ and methyl-nicotinamide. The work established metabolic handling of exogenous NAD+ but did not test clinical recovery or healthspan outcomes.

In 2026, a U.S.-based retrospective real-world study compared four consecutive days of IV NAD+ with IV NR. NAD+ recipients reported more moderate-to-severe infusion symptoms, including gastrointestinal symptoms, tachycardia and chest pressure, and required longer infusion times. Routine liver, renal and inflammatory laboratory markers did not show major short-term changes. Because the study was retrospective, commercially delivered and not placebo-controlled, it is best viewed as tolerability evidence, not efficacy proof.

The 2026 systematic review in Ageing Research Reviews is the clearest evidence synthesis: oral NR/NMN reliably changed NAD-related biomarkers, but clinically meaningful human outcomes were heterogeneous, and no eligible outcome trial evaluated IV or intramuscular NAD+ itself for anti-aging or wellness. A separate 2026 Finnish study measuring NAD and glutathione redox metabolites emphasized that NAD(H), NADP(H) and GSH/GSSG form interconnected but distinct redox pools and that human reference ranges and treatment-response interpretation remain under development.

Glutathione - United States, Asia and International Clinical Research

U.S. randomized research demonstrated that oral glutathione can raise body stores over six months, while an earlier four-week randomized study in healthy volunteers found no significant improvement in its primary systemic oxidative-stress biomarkers. In Thailand, small randomized dermatology studies reported modest changes in melanin indices, illustrating that glutathione effects can be tissue- and endpoint-specific rather than broadly systemic.

Small IV studies have likewise produced limited clinical conclusions. The U.S. Parkinson disease pilot found no statistically significant clinical improvement. A small coronary-angiography study reported suppression of acute renal oxidative-stress markers with IV glutathione, but the sample was too small to establish major clinical renal protection. The overall human literature supports biochemical redox activity more strongly than broad therapeutic efficacy.

Product quality is currently a major translational issue. On August 27, 2026, FDA warned that at least 30 patients had experienced adverse events after IV glutathione compounded using dietary-supplement-grade material, with endotoxin-related reactions including fever, chills, hypotension and sepsis-like symptoms. This event concerns ingredient quality and sterile compounding, but it directly limits how safely injectable-glutathione research can be generalized.

Sermorelin / GHRH(1-29) - United States and Multicenter Human Research

NIH investigators showed in 1992 that GHRH(1-29) could reverse age-associated reductions in GH and IGF-1 in a small group of older men during short-term treatment. In pediatric GH deficiency, a multicenter international study of once-daily GHRH(1-29) increased height velocity during the first year, supporting the historical Geref development program.

The broader GHRH literature extends beyond exact sermorelin. Studies of modified GHRH(1-29) analogs and longer-duration GHRH treatment in older adults reported increases in IGF-1, selected body-composition changes and, in one randomized trial, cognitive signals. These studies demonstrate that stimulating the hypothalamic-pituitary somatotropic axis can produce systemic effects, but they do not validate commercial sermorelin protocols for general anti-aging or recovery.

Regulatory history is important. FDA records show that Geref/sermorelin acetate was approved for pediatric growth-hormone deficiency, later withdrawn from the U.S. market, and formally determined not to have been discontinued for reasons of safety or effectiveness. That historical approval does not mean current compounded sermorelin products are FDA-approved for anti-aging or adult wellness uses.

Direct Research on NAD+ + Glutathione + Sermorelin Together

No peer-reviewed trial, prospective observational study, animal experiment or cell study was identified that administered all three components together as a defined intervention. No study was identified comparing sermorelin alone with sermorelin plus NAD+, glutathione, or both. No pharmacokinetic study establishes whether parenteral NAD+ or glutathione changes sermorelin exposure, GH pulsatility or IGF-1 response.

Pairwise biological relationships exist, but they are not combination evidence. NAD(H)/NADP(H) and glutathione redox systems interact metabolically, and GH/IGF-1 signaling changes energy use and anabolic metabolism. These connections support a research hypothesis; they do not demonstrate that co-administration improves recovery, body composition, cognition, longevity or tissue repair.

Theory of the Stack - How the Combination Could Work

1. Cellular Bioenergetics - NAD+ Layer

NAD+ would provide the cellular-energy and signaling layer. Adequate NAD+ supports oxidative metabolism, mitochondrial electron transfer and NAD+-dependent enzymes involved in metabolic adaptation and DNA repair. The theory is strongest at the level of cellular physiology, not as proof that IV NAD+ produces superior whole-body outcomes.

2. Redox Buffering - Glutathione Layer

Glutathione would provide the direct intracellular thiol-buffer layer. GSH participates in peroxide detoxification and is regenerated from GSSG by glutathione reductase using NADPH. This creates a clear mechanistic reason to study NAD-related metabolism and GSH together under oxidative stress.

3. Endocrine / Repair Signaling - Sermorelin Layer

Sermorelin would provide the endocrine layer by stimulating endogenous GH release and raising IGF-1 when the pituitary axis is responsive. In theory, that signal could influence protein synthesis, tissue turnover, substrate use and body composition. The effect is endocrine and systemic rather than a direct antioxidant or mitochondrial intervention.

4. NAD+ and Glutathione Are Connected - but NAD+ Is Not NADPH

A critical biochemical distinction is that NAD+ does not directly reduce oxidized glutathione. NAD+ can be phosphorylated to NADP+ by NAD kinase, and cellular pathways reduce NADP+ to NADPH; NADPH then supplies the reducing equivalents used by glutathione reductase to regenerate GSH. This makes the pathways connected, but it does not prove that infusing NAD+ increases intracellular NADPH or improves GSH recycling in humans.

5. Energy + Redox Support Could Theoretically Buffer Anabolic Demand

GH/IGF-1 signaling can increase protein turnover, nutrient use and tissue remodeling. A plausible theory is that adequate bioenergetic capacity and redox buffering could support cells during increased anabolic activity. NAD+ would theoretically support energy and stress signaling, glutathione would manage redox load, and sermorelin would provide the growth/recovery signal. This three-layer model is mechanistically coherent but has never been experimentally validated as a stack.

6. The Pathways Are Complementary Rather Than Receptor-Redundant

The three components do not primarily compete for the same receptor or enzyme. Sermorelin acts at the GHRH receptor, NAD+ participates in cofactor and signaling networks, and glutathione acts as a redox buffer and enzyme substrate. This lowers simple receptor redundancy and makes the stack more conceptually integrated than combinations containing two drugs that target the same receptor system.

7. More Reducing Power Is Not Automatically Better

Redox biology requires balance. Excessively reduced NADH/NADPH/GSH states can produce reductive stress, just as excessive oxidation can cause oxidative stress. Therefore, combining multiple “antioxidant” or redox-support concepts should not be interpreted as automatically additive. The research goal should be normalization of redox state, not maximal reduction.

8. GH/IGF-1 Signaling Creates Separate Metabolic and Proliferative Questions

Raising GH/IGF-1 can alter insulin sensitivity, fluid balance and tissue growth. Exact short-term GHRH(1-29) studies did not necessarily worsen fasting glucose, but longer GHRH studies found increases in fasting insulin in some participants. Any combined study should monitor glucose, insulin and IGF-1. Because IGF-1 is a growth signal, active malignancy or proliferative disease would also be an important exclusion/safety consideration in formal research.

9. Injectable Product Quality Could Overwhelm the Biological Theory

Both NAD+ and glutathione are used in commercial IV settings despite limited outcomes evidence. FDA has separately warned about food-grade NAD+ being used in sterile compounding and about dietary-supplement-grade glutathione used for injectable products. Endotoxin or sterility problems can create adverse events unrelated to the intended biology and must be treated as a major research variable.

10. The Most Coherent Research Question Is Metabolic Recovery, Not “Anti-Aging”

A scientifically defensible study would ask whether the stack changes defined biomarkers or functional outcomes - for example NAD metabolome, GSH/GSSG, oxidative-stress markers, GH pulsatility, IGF-1, body composition, muscle recovery or physical function. A broad claim that the stack reverses aging, detoxifies the body or extends lifespan is far beyond the available evidence.

Possible Overall Benefit - Theoretical, Not Proven

The most defensible theoretical benefit of NAD+ + glutathione + sermorelin is coordinated support of three different physiological layers: cellular bioenergetics and NAD-dependent signaling, intracellular redox defense, and endogenous GH-IGF-1 endocrine signaling. In a recovery or age-related physiology model, the combination could theoretically create a more favorable cellular environment for tissue turnover by pairing an anabolic signal with energy and redox support.

The theory is biologically complementary, but the clinical evidence is weak for the stack as a whole. Sermorelin/GHRH has genuine human endocrine activity; glutathione has direct human redox and supplementation evidence; direct NAD+ has human pharmacokinetic and short-term tolerability data but little proof of meaningful clinical outcomes. No evidence shows that adding NAD+ and glutathione improves the GH/IGF-1 response to sermorelin or that sermorelin improves the functional consequences of NAD+ or glutathione supplementation.

The most realistic expected research signal would therefore be changes in biomarkers rather than dramatic changes in strength, fat loss, cognition, longevity or tissue regeneration. Any overall performance or anti-aging benefit remains a hypothesis.

Why More Research Is Needed

No published human, animal or cell study has tested the complete NAD+ + glutathione + sermorelin combination.

No study has established whether NAD+ or glutathione changes sermorelin pharmacokinetics, GH pulsatility or IGF-1 response.

Direct IV NAD+ has very limited outcomes evidence; the strongest human NAD-boosting literature is for NR/NMN and should not be treated as equivalent to IV NAD+.

The 2026 systematic review found no eligible IV/IM NAD+ outcomes trials for anti-aging or wellness.

IV NAD+ can cause substantial infusion-related symptoms in preliminary real-world data, and FDA has warned about inappropriate food-grade material used in sterile NAD+ compounding.

Glutathione can improve measurable redox status, but clinical benefits are indication and route dependent and are not universally demonstrated.

FDA reported at least 30 adverse events in 2026 linked to IV glutathione compounded from dietary-supplement-grade material, highlighting product-quality risk.

Sermorelin/GHRH data are real but much of the exact sermorelin literature is older, pediatric, short term, or focused on endocrine endpoints rather than hard clinical outcomes.

Adjacent GHRH analog studies cannot automatically be treated as exact sermorelin evidence.

GH/IGF-1 stimulation can alter insulin, glucose handling, fluid balance and proliferative signaling, requiring dedicated metabolic and safety monitoring.

NAD(H), NADP(H) and GSH/GSSG are distinct compartmentalized redox pools; increasing one pool does not guarantee improvement of another.

A valid study should include sermorelin alone, NAD+ alone, glutathione alone, relevant pairwise combinations, the three-way combination and placebo/control arms.

Endpoints should include NAD metabolomics, GSH/GSSG, oxidative-stress markers, GH/IGF-1, glucose/insulin, body composition, physical function, adverse events and product-quality testing.

Research Summary

NAD+ + glutathione + sermorelin is a mechanistically coherent but clinically unvalidated bioenergetic-redox-endocrine stack. Sermorelin has the strongest direct endocrine pharmacology: GHRH(1-29) raises endogenous GH and IGF-1, and historical pediatric studies demonstrated increased growth velocity in GH deficiency. Glutathione has strong endogenous biology and randomized human evidence that oral supplementation can raise body GSH stores, although disease-level outcomes are inconsistent and injectable-product quality remains a current safety issue.

NAD+ is biologically essential, but direct parenteral NAD+ has the weakest clinical efficacy evidence of the three. Human studies show metabolic handling and short-term tolerability, while a 2026 systematic review found no eligible IV/IM NAD+ outcomes trials for anti-aging or wellness. The larger NR/NMN literature demonstrates biochemical target engagement but mixed functional results and cannot be used as proof that direct NAD+ infusion is effective.

The stack theory is strongest as a three-layer research hypothesis: sermorelin provides a GH-IGF-1 signal, NAD-related metabolism supports cellular energy and signaling, and glutathione provides redox buffering. The same model has important limits: NAD+ is not the same as NADPH, excess reduction can create reductive stress, and GH/IGF-1 stimulation introduces glucose, fluid and proliferative considerations. No direct combination study has demonstrated superior recovery, body composition, cognition, longevity or tissue repair.

Selected Sources

Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PMID: 41655607. DOI: 10.1016/j.arr.2026.103057.

Grant R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257. PMID: 31572171. PMCID: PMC6751327. DOI: 10.3389/fnagi.2019.00257.

Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID: 41704678. PMCID: PMC12907335. DOI: 10.3389/fragi.2026.1652582.

Euro L, et al. Dynamics of blood NAD and glutathione in health, disease, aging, and under NAD+-booster treatment. Redox Biol. 2026;96:104343. PMID: 42628241. DOI: 10.1016/j.redox.2026.104343.

Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. PMID: 24791752. DOI: 10.1007/s00394-014-0706-z.

Hauser RA, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson disease. Mov Disord. 2009;24(7):979-983. PMID: 19230029. DOI: 10.1002/mds.22401.

Visca A, et al. Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial. J Pediatr Gastroenterol Nutr. 2020. PMID: 32960827.

U.S. Food and Drug Administration. FDA reminds compounders not to use dietary supplement grade glutathione for injectables. August 27, 2026.

U.S. Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding. Warning includes use of food-grade NAD+ in intravenous products and reported endotoxin-consistent adverse events.

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256. DOI: 10.1210/jcem.75.2.1379256.

Geref International Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996. PMID: 8772599.

Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141536. DOI: 10.1210/jcem.82.5.3943.

Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012. PMID: 22869065. DOI: 10.1001/archneurol.2012.1970.

U.S. Food and Drug Administration. Geref (sermorelin acetate) approval/orphan-drug records; FDA determination that the product was not withdrawn for safety or effectiveness reasons.

Kawai S, Murata K. Molecular properties, functions, and potential applications of NAD kinases. Appl Microbiol Biotechnol. 2009. PMID: 19430699.

Xiao W, et al. Homeostatic regulation of NAD(H) and NADP(H) in cells. 2024. PMID: 38988322. Review of NADK, NADPH generation and glutathione-reductase redox coupling.

Theory vs. Proof - Verdict

What is supported by evidence: NAD+ is an essential cellular redox and metabolic cofactor; direct IV NAD+ is metabolized in humans and has preliminary short-term tolerability data; oral glutathione can increase measurable body glutathione stores; glutathione is a central NADPH-supported redox buffer; and sermorelin/GHRH(1-29) can increase endogenous GH and IGF-1 in humans, with historical evidence for improved growth velocity in GH-deficient children.

What is not proven: that IV NAD+ improves recovery, energy, cognition, body composition, longevity or healthspan; that glutathione provides broad clinical benefit outside specific studied settings; that NAD+ infusion meaningfully raises intracellular NADPH or improves glutathione recycling; that sermorelin is an effective anti-aging or general body-composition therapy; or that combining NAD+ + glutathione + sermorelin is additive, synergistic, safer or more effective than the components alone.

Verdict - theory vs. proof: the mechanistic theory is moderately strong and genuinely complementary, but the clinical proof is weak for the complete stack. Sermorelin supplies a distinct endocrine GH-IGF-1 signal, glutathione supplies direct redox buffering, and NAD-related metabolism supplies a plausible cellular-energy and signaling layer. The strongest scientific rationale is coordinated metabolic recovery rather than “anti-aging.” However, direct NAD+ outcomes evidence is sparse, the NAD+-to-glutathione link depends on intermediary NADP+/NADPH biology rather than direct reduction by NAD+, and GH/IGF-1 stimulation introduces separate metabolic and proliferative uncertainties. Overall, NAD+ + glutathione + sermorelin is best classified as a biologically coherent but clinically unproven recovery/metabolic-aging hypothesis with real human evidence for each component at different levels, no direct three-way evidence, and significant route/product-quality considerations for injectable NAD+ and glutathione.

Research & Educational Use Only !!